206 related articles for article (PubMed ID: 31662149)
1. Haematopoietic stem cell transplantation in South Africa: Current limitations and future perspectives.
Grobbelaar S; Mercier AE; Verburgh E; Brittain D; Pepper MS
S Afr Med J; 2019 Sep; 109(8b):46-52. PubMed ID: 31662149
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Haematopoietic stem cell transplants: principles and indications.
Balassa K; Danby R; Rocha V
Br J Hosp Med (Lond); 2019 Jan; 80(1):33-39. PubMed ID: 30592675
[TBL] [Abstract][Full Text] [Related]
4. Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!
Kindwall-Keller TL; Ballen KK
Oncologist; 2017 Sep; 22(9):1125-1134. PubMed ID: 28546462
[TBL] [Abstract][Full Text] [Related]
5. Impact of outpatient non-myeloablative haematopoietic stem cell transplantation in quality of life vs. conventional therapy.
Cantú-Rodríguez OG; Sánchez-Cárdenas M; Treviño-Montemayor OR; Gutiérrez-Aguirre CH; Tarín-Arzaga L; Jaime-Pérez JC; Gómez-Almaguer D
Psychol Health Med; 2016; 21(1):10-9. PubMed ID: 26125120
[TBL] [Abstract][Full Text] [Related]
6. Graft-versus-host disease.
Shlomchik WD
Nat Rev Immunol; 2007 May; 7(5):340-52. PubMed ID: 17438575
[TBL] [Abstract][Full Text] [Related]
7. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
Kallekleiv M; Larun L; Bruserud Ø; Hatfield KJ
Cytotherapy; 2016 Feb; 18(2):172-85. PubMed ID: 26794711
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
9. Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease.
Cuthbertson P; Geraghty NJ; Adhikary SR; Bird KM; Fuller SJ; Watson D; Sluyter R
Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361109
[TBL] [Abstract][Full Text] [Related]
10. [Allogeneic hematopoietic stem cell treatment after non-myeloablation (minigraft)].
Baron F
Bull Mem Acad R Med Belg; 2011; 166(1-2):39-45; discussion 46-8. PubMed ID: 22375489
[TBL] [Abstract][Full Text] [Related]
11. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
12. Adoptive allogeneic immunotherapy--history and future perspectives.
Schleuning M
Transfus Sci; 2000 Oct; 23(2):133-50. PubMed ID: 11035275
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner.
Passweg JR; Halter J; Bucher C; Gerull S; Heim D; Rovó A; Buser A; Stern M; Tichelli A
Swiss Med Wkly; 2012; 142():w13696. PubMed ID: 23135685
[TBL] [Abstract][Full Text] [Related]
14. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases.
Maris M; Storb R
Immunol Res; 2003; 28(1):13-24. PubMed ID: 12947221
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
[TBL] [Abstract][Full Text] [Related]
16. Increased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: a systematic review.
Fisher SA; Lamikanra A; Dorée C; Gration B; Tsang P; Danby RD; Roberts DJ
Br J Haematol; 2017 Feb; 176(3):448-463. PubMed ID: 28094847
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
18. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
19. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
20. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
